13-valent pneumococcal polysaccharide conjugate vaccine (CanSino Biologics)

13价肺炎球菌多糖结合疫苗 (CanSino Biologics)

Report date: 2026/02/28 20:00:37

Base Information

Drug Name13-valent pneumococcal polysaccharide conjugate vaccine (CanSino Biologics)
Drug Alias Name13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT)优佩欣iPneuciaCRM197,TTPCV13i
ClassificationVaccines > Vaccine type > Multivalent vaccineVaccines > Development/production technology > Conjugated vaccineVaccines > Biological material > Bacterial vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPneumonia, PneumococcalPneumococcal InfectionsStreptococcal Infections +[4] 
Global Approved IndicationsPneumococcal Infections
Approved Indications in ChinaPneumococcal Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2025/06/17
Country/TerritoryThailandMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTianjin Cansino Biotechnology Inc
China Registration ClassN/A

Develop Information

Active CompaniesCanSino Biologics IncTianjin Cansino Biotechnology Inc
Inactive CompaniesN/A
Active IndicationsPneumonia, PneumococcalPneumococcal InfectionsStreptococcal Infections +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A